In 2006, I-MAK began working to increase access to treatment for HIV in India. Today, the organization’s legal work and research has expanded to 49 countries and 20 treatments for eight diseases, including hepatitis C, HIV, leukemia, tuberculosis, diabetes, cancer, and blood-related disorders. Worldwide, for HIV treatments alone, I-MAK has helped government health programs save more than $1 billion in the last 12 years.
REDUCED prices FOR HIV drugs in India, CATALYZING SAVINGS worldWIDE
As a result of I-MAK’s successful patent challenges on four HIV drugs in India, prices for these lifesaving generic medicines are now 51-89% lower than the branded versions. These wins supplied low and middle income countries worldwide with low-cost generics, saving an estimated $500 million – money that could be reinvested to treat more than one million people.
PUBLIC HEALTH PROGRAMS SAVE HALF A BILLION DOLLARS PER YEAR IN FOUR COUNTRIES
I-MAK has worked alongside five patient advocacy organizations since 2014 to reduce drug prices in Argentina, Brazil, Thailand, and Ukraine.* Patent challenges, drug pricing negotiations, and policy dialogues between the public and private sectors on 15 HIV drugs in these four countries have contributed to price reductions in four countries, which are saving health programs an estimated $472 million each year.
ONGOING PATENT CHALLENGES IN FIVE COUNTRIES COULD HELP TREAT MILLIONS MORE PEOPLE AND SAVE BILLIONS OF DOLLARS WORLDWIDE
In 2015, I-MAK filed a patent challenge against Sovaldi® in China, and worked with partner organizations to file similar challenges in Argentina, Brazil, Russia, and Ukraine. In China alone there is potential to save $13 billion and treat an additional 1.5 million people if only 15% of infections are treated (similar to treatment rate for HIV). If these cases are successful, these five countries have the potential to increase access to treatment for millions people, open up the market for more competition, and save government health programs billions.